StockNews.com Begins Coverage on Catalent (NYSE:CTLT)

StockNews.com started coverage on shares of Catalent (NYSE:CTLT) in a report issued on Thursday. The firm issued a sell rating on the stock.

A number of other brokerages have also issued reports on CTLT. William Blair reiterated a market perform rating on shares of Catalent in a report on Tuesday, September 3rd. Baird R W lowered shares of Catalent from a strong-buy rating to a hold rating in a report on Tuesday, September 24th. Robert W. Baird restated a neutral rating and set a $63.50 price target on shares of Catalent in a report on Tuesday, September 24th. Royal Bank of Canada restated a sector perform rating and set a $63.50 price target on shares of Catalent in a report on Thursday, July 11th. Finally, Barclays raised their price target on shares of Catalent from $47.00 to $63.00 and gave the stock an equal weight rating in a report on Friday, June 28th. One analyst has rated the stock with a sell rating and eight have issued a hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of Hold and an average target price of $59.83.

Catalent Trading Up 0.1 %

CTLT opened at $60.33 on Thursday. The company’s 50 day moving average is $59.69 and its 200-day moving average is $57.34. Catalent has a 1-year low of $31.80 and a 1-year high of $61.20. The company has a current ratio of 2.52, a quick ratio of 1.96 and a debt-to-equity ratio of 1.35. The company has a market cap of $10.92 billion, a P/E ratio of -9.89, a PEG ratio of 2.32 and a beta of 1.15.

Catalent (NYSE:CTLT) last issued its quarterly earnings data on Thursday, August 29th. The company reported $0.57 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.44 by $0.13. The business had revenue of $1.30 billion during the quarter, compared to analyst estimates of $1.23 billion. Catalent had a negative net margin of 22.72% and a negative return on equity of 0.56%. Equities research analysts predict that Catalent will post 0.85 earnings per share for the current fiscal year.

Insider Transactions at Catalent

In other news, insider Ricky Hopson sold 662 shares of the firm’s stock in a transaction that occurred on Friday, August 2nd. The shares were sold at an average price of $59.56, for a total transaction of $39,428.72. Following the completion of the sale, the insider now owns 29,974 shares of the company’s stock, valued at approximately $1,785,251.44. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In related news, CFO Matti Masanovich sold 2,993 shares of Catalent stock in a transaction on Monday, July 8th. The shares were sold at an average price of $56.74, for a total value of $169,822.82. Following the completion of the sale, the chief financial officer now owns 33,871 shares of the company’s stock, valued at approximately $1,921,840.54. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider Ricky Hopson sold 662 shares of Catalent stock in a transaction on Friday, August 2nd. The shares were sold at an average price of $59.56, for a total transaction of $39,428.72. Following the completion of the sale, the insider now directly owns 29,974 shares of the company’s stock, valued at approximately $1,785,251.44. The disclosure for this sale can be found here. Insiders sold a total of 15,403 shares of company stock valued at $902,503 in the last quarter. 0.31% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Catalent

A number of hedge funds have recently bought and sold shares of the company. Nisa Investment Advisors LLC boosted its holdings in Catalent by 1.7% during the 2nd quarter. Nisa Investment Advisors LLC now owns 11,013 shares of the company’s stock worth $619,000 after acquiring an additional 185 shares during the last quarter. Lindbrook Capital LLC boosted its holdings in Catalent by 79.4% during the 1st quarter. Lindbrook Capital LLC now owns 470 shares of the company’s stock worth $27,000 after acquiring an additional 208 shares during the last quarter. GAMMA Investing LLC boosted its holdings in Catalent by 25.9% during the 2nd quarter. GAMMA Investing LLC now owns 1,032 shares of the company’s stock worth $58,000 after acquiring an additional 212 shares during the last quarter. Czech National Bank boosted its holdings in Catalent by 0.7% during the 1st quarter. Czech National Bank now owns 31,801 shares of the company’s stock worth $1,795,000 after acquiring an additional 228 shares during the last quarter. Finally, Sumitomo Mitsui DS Asset Management Company Ltd boosted its holdings in Catalent by 1.4% during the 2nd quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 19,238 shares of the company’s stock worth $1,082,000 after acquiring an additional 257 shares during the last quarter.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.